MX386393B - Andrografólido para tratar formas progresivas de esclerosis múltiple. - Google Patents
Andrografólido para tratar formas progresivas de esclerosis múltiple.Info
- Publication number
- MX386393B MX386393B MX2018015208A MX2018015208A MX386393B MX 386393 B MX386393 B MX 386393B MX 2018015208 A MX2018015208 A MX 2018015208A MX 2018015208 A MX2018015208 A MX 2018015208A MX 386393 B MX386393 B MX 386393B
- Authority
- MX
- Mexico
- Prior art keywords
- andrographolide
- multiple sclerosis
- treatment
- progressive forms
- progressive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662347218P | 2016-06-08 | 2016-06-08 | |
| PCT/US2017/036463 WO2017214346A1 (en) | 2016-06-08 | 2017-06-08 | Andrographolide treats progressive forms of multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018015208A MX2018015208A (es) | 2019-09-19 |
| MX386393B true MX386393B (es) | 2025-03-18 |
Family
ID=60578163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015208A MX386393B (es) | 2016-06-08 | 2017-06-08 | Andrografólido para tratar formas progresivas de esclerosis múltiple. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10722492B2 (enExample) |
| EP (1) | EP3468553B1 (enExample) |
| JP (2) | JP6928963B2 (enExample) |
| CN (1) | CN109562097B (enExample) |
| CA (1) | CA3026770C (enExample) |
| DK (1) | DK3468553T3 (enExample) |
| MX (1) | MX386393B (enExample) |
| WO (1) | WO2017214346A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019126759A1 (en) * | 2017-12-22 | 2019-06-27 | Convelo Therapeutics, Inc. | Compounds and methods of promoting myelination |
| CN109293607A (zh) * | 2018-11-14 | 2019-02-01 | 株洲千金药业股份有限公司 | 一种具有抗炎作用的化合物及其在制备抗炎药物中的应用 |
| CN109223770A (zh) * | 2018-11-14 | 2019-01-18 | 株洲千金药业股份有限公司 | 一种具有镇痛作用的化合物及其在制备镇痛药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003059387A2 (en) * | 2001-12-21 | 2003-07-24 | Ilex Oncology, Inc. | Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis |
| KR20070026398A (ko) * | 2004-02-03 | 2007-03-08 | 우니베르시다드 오스뜨랄 데 칠레 | Ppar-감마 수용체의 활성화에 의한 자가면역 질환 및알츠하이머병의 치료에 유용한, 천심련으로부터 추출된랍단 디테르펜을 포함하는 조성물 |
| JP5936707B2 (ja) * | 2011-12-21 | 2016-06-22 | イノバイオサイエンス, エルエルシー | インターフェロンおよびアンドログラホリドを用いた多発性硬化症のための併用療法 |
-
2017
- 2017-06-08 JP JP2018564301A patent/JP6928963B2/ja active Active
- 2017-06-08 WO PCT/US2017/036463 patent/WO2017214346A1/en not_active Ceased
- 2017-06-08 DK DK17810987.2T patent/DK3468553T3/da active
- 2017-06-08 MX MX2018015208A patent/MX386393B/es unknown
- 2017-06-08 CN CN201780035899.2A patent/CN109562097B/zh active Active
- 2017-06-08 EP EP17810987.2A patent/EP3468553B1/en active Active
- 2017-06-08 US US15/774,604 patent/US10722492B2/en active Active
- 2017-06-08 CA CA3026770A patent/CA3026770C/en active Active
-
2021
- 2021-07-08 JP JP2021113384A patent/JP2021165304A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3468553A4 (en) | 2020-02-12 |
| CN109562097B (zh) | 2022-06-07 |
| EP3468553B1 (en) | 2023-05-24 |
| EP3468553A1 (en) | 2019-04-17 |
| US20190083458A1 (en) | 2019-03-21 |
| US10722492B2 (en) | 2020-07-28 |
| DK3468553T3 (da) | 2023-07-03 |
| JP2021165304A (ja) | 2021-10-14 |
| WO2017214346A1 (en) | 2017-12-14 |
| JP6928963B2 (ja) | 2021-09-01 |
| JP2019517550A (ja) | 2019-06-24 |
| CA3026770C (en) | 2024-05-28 |
| CA3026770A1 (en) | 2017-12-14 |
| CN109562097A (zh) | 2019-04-02 |
| MX2018015208A (es) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122344T1 (el) | Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων | |
| DOP2017000025A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| BR112019005908A2 (pt) | uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres | |
| CR20160069A (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| MX2015003140A (es) | Formulaciones de enzalutamida. | |
| MX380252B (es) | Crenezumab para usarse en el tratamiento de enfermedad de alzheimer. | |
| PT3481846T (pt) | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda | |
| GT201600027A (es) | Inhibidores de rorc2 y sus métodos de uso | |
| UY35693A (es) | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso | |
| GT201600002A (es) | Bencil-1h-pirazolo[3,4-b]piridinas y su uso | |
| MX388722B (es) | Compuestos para tratar el cancer de ovario. | |
| SV2018005783A (es) | 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]piridin-3(2h)-onas y 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones sustituidas su uso | |
| MX2018012285A (es) | Metodos de tratamiento para enfermedades colestasicas y fibroticas. | |
| ZA202002779B (en) | Dantrolene prodrugs and methods of their use | |
| MX379359B (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| CL2021002318A1 (es) | Métodos de tratamiento de amiloidosis al | |
| IL287704A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| UY37671A (es) | N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso | |
| MX386393B (es) | Andrografólido para tratar formas progresivas de esclerosis múltiple. | |
| NI201900023A (es) | 1 - arilnaftiridin-3-carboxamidas 7-sustituidas y su uso | |
| EA201791819A1 (ru) | Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. | |
| MX2021002444A (es) | Compuestos y metodos para el tratamiento de infecciones fungicas. | |
| CL2021001554A1 (es) | Métodos para el tratamiento de discinesia en parálisis cerebral. |